Meridian Assay

Independent analytical testing - Cambridge MA

TASK NO.
EKJT2B3
Report MA-BLD-0008 - Rev. 01

CERTIFICATE OF ANALYSIS

BPC-157 + TB-500 Blend - 20 mg total


Two-peptide blend - 10 mg BPC-157 plus 10 mg TB-500

Material	BPC-157 + TB-500 Blend	Client	novumpeptides.com	Received	2026-04-25 at 2-8 C
Batch / lot	BLD-08-2B3	Label claim	20 mg total	Analysed	2026-04-26 to 2026-04-27

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Component identity	**All conform**	Match references	MA-MS-025 / LC-HRMS	Conforms
Peptide-related purity	**99.53%**	>= 99.00%	MA-MULTI-014 / UHPLC-UV	Pass
BPC-157 per vial	**10.00 mg**	9.00-11.00 mg	MA-MULTI-014 / UHPLC-MS	Pass
TB-500 per vial	**10.01 mg**	9.00-11.00 mg	MA-MULTI-014 / UHPLC-MS	Pass
Total active content	**20.01 mg**	18.00-22.00 mg	Calculated from component assays	Pass
Water content	**3.87%**	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	**158 ppm**	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	**0.12%**	<= 1.00%	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record EKJT2B3-BLD-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.14%
insertion sequence	0.10%
diastereomeric variant	0.08%
N-terminal variant	0.06%
C-terminal variant	0.04%
unresolved peaks	0.05%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Multiplex LC-MS confirmed every declared component. Individual assays were 10.00 mg BPC-157, 10.01 mg TB-500; peptide-related chromatographic purity was 99.53%.

Blend content was quantified component-by-component against qualified references. The purity figure describes resolved peptide-related substances, not the proportion of any one component.

Analytical review
Ines Abadi I.Abadi

Quality review
Marcus Oyelaran
Approval date: 2026-04-28 M.Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.